N/A N=42 755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars
Benign Pigmented and Vascular Lesions and Scars
Primary: Clearance Based on Photographic Scale — 2; 2; 4; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=204 Vitamin D Levels in Frail Elderly Patients With a Hip Fracture
Hip Fracture · Vitamin D Deficiency
Primary: Number of Participants With Suboptimal and Optimal Levels of Vitamin D (Serum-25(OH)D) — 106; 42; 15; 41 Participants
Phase 1 N=90 Study of the Gut Hormone Analogue G3215 in Adult Subjects
Diabetes Mellitus · Obesity
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] — 2; 0; 0; 3 Participants
N/A N=89 A Study to Evaluate Two Different Surgical Methods for Treatment for Abdominal Wall Diastasis
Abdominal Hernias and Other Abdominal Wall Conditions · Post-operative Pain · Recurrence
Primary: Recurrence of Diastasis One Year Post-operatively That Indicated by CT Scan or Clinical Investigation. — 2; 3; 26 Participants
Phase 2 N=36 A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Primary: Percentage of Participants With Complete Response (CR) During Acute Period (0 to 24 Hours) After Receiving Treatment on Day 1 — 88.2 percentage of participants
Phase 2 N=29 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
Biliary Tract Cancer
Primary: Objective Response Rate (ORR) — 11.5 percentage of participant
Phase 3 N=1,186 Safety and Efficacy in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.6; 12.0 Percentage of participants — p=0.0006
N/A N=90 Stroke and CPAP Outcome Study 2
Sleep Apnea, Obstructive · Stroke · Patient Adherence
Primary: 3-month CPAP Adherence — 32 participants adherent to CPAP at 90 days
N/A N=50 Study of Basivertebral Nerve Ablation Treatment of Chronic Low Back Pain
Chronic Low Back Pain
Primary: Oswestry Disability Index (ODI) - 3 Months — -30.33 units on a scale — p=<0.001
Phase 2 N=21 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants
Phase 2 N=34 Pilot of Zinc Acetate to Improve Chronic Cough
Cough
Primary: Change in Cough Quality of Life Questionnaire (CQLQ) Score by Treatment Group — -5.00; -6.00 score on a scale
Phase 2 N=114 De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: 2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous…
Phase 3 N=76 13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
Acute Liver Failure
Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
N/A N=234 The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)
Hemorrhage
Primary: Hemostatic Success at 5 Minutes — 109; 103 Participants — p=<0.0001
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants